Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06491615 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor 4 versions Re-verified since May 24, 2025, no change to tracked fieldsv24-v27
  2. Minor Site contacts updated at 1 of 2 sitesv23
  3. Minor 3 versions Re-verified since Mar 19, 2025, no change to tracked fieldsv20-v22
  4. Minor Site contacts updated at 1 of 2 sitesv19
  5. Minor Re-verified, no change to tracked fieldsv18
Show 16 earlier versionsHide 16 earlier versions
  1. Minor Eligibility criteria expanded, about 50 wordsv17
  2. Notable Enrollment target: 100 to 1000v16
  3. Minor 3 versions Re-verified since Aug 14, 2024, no change to tracked fieldsv13-v15
  4. Minor Start date changed from estimate of Jul 29, 2024 to Jul 12, 2024v12
  5. Minor Start date: Jul 28, 2024 to Jul 29, 2024v11
  6. Minor Start date: Jul 25, 2024 to Jul 28, 2024v10
  7. Minor Start date: Jul 24, 2024 to Jul 25, 2024v9
  8. Minor Start date: Jul 23, 2024 to Jul 24, 2024v8
  9. Minor Start date: Jul 22, 2024 to Jul 23, 2024v7
  10. Minor Start date: Jul 21, 2024 to Jul 22, 2024v6
  11. Minor Start date: Jul 18, 2024 to Jul 21, 2024v5
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 17, 2024 to Jul 18, 2024
    • Site details revised at 2 of 2 sites
    v4
  13. Minor Start date: Jul 15, 2024 to Jul 17, 2024
    • Study description expanded, about 4 words
    • Study title expanded, about 2 words
    v3
  14. Minor Start date: Jul 14, 2024 to Jul 15, 2024v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases. These findings helped them create better treatments. Now researchers want to expand eyeGENE (Registered Trademark) to include more people for certain eye diseases. Objective: To collect information and DNA samples for the study of eye diseases. * Primary objective --To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual * Secondary objectives * To enhance recruitment for clinical trials and investigations in inherited eye diseases * To establish genotype-phenotype correlations for rare eye diseases Eligibility: People of any age with certain eye diseases. These can include aniridia; Best disease; blue-cone monochromacy; corneal dystrophy; and disorders of pigmentation, such as albinism. Relatives unaffected by the eye disease of interest may also be needed. Design: Researchers will select participants based on their diagnosis. The data may include images and test results from eye exams. Participants will provide a sample of saliva. They will receive a kit with written instructions. They will spit in a tube and mail it to the NIH. Participants may be asked to provide a blood sample. The blood may be drawn at the NIH or at a local clinic. The eyeGENE (Registered Trademark) repository will offer researchers data about the participants eye conditions. The data may include pictures of their eyes, results of the genetic testing, and history of other diseases. Researchers will be able to see data such as age and gender, but they will not see names, dates of birth, or contact information.
Trial Details
NCT Number NCT06491615
Lead Sponsor National Eye Institute (NEI)
Conditions
(from sponsor)
Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Related terms Albinism, Aniridia, Blue cone monochromatism, Corneal Dystrophies, Hereditary, Vitelliform Macular Dystrophy, Vitiligo
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov